ADAPY
Adaptimmune Therapeutics plc
Healthcare · Biotechnology · PNK
$0.03
Data: 2026-05-18
✗ ETHICAL FAIL
MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$7M
Total market value of the company
0.00
Rev Growth
-89.3%
Year-over-year revenue change
Profit Margin
-260.8%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Adaptimmune Therapeutics plc
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
706.4% FAIL
Debt must be below 33% of total assets
Cash Ratio
378.2% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-90.9%
Historical annualised return based on price data
Days in State
10
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-08-28 | BERTRAND WILLIAM C JR | Chief Operating Officer | 207,000 | $14,262 | |
| 2025-08-18 | BEHBAHANI ALI | Director | 19,500,000 | $1,314,304 | |
| 2025-07-30 | ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 64,052,538 | $6,890,236 | |
| 2025-01-17 | BERTRAND WILLIAM C JR | Chief Operating Officer | 5,584 | $3,243 | |
| 2025-01-17 | RAWCLIFFE ADRIAN | Chief Executive Officer | 30,601 | $17,773 | |
| 2025-01-17 | LUNGER JOHN | Officer | 5,584 | $3,243 | |
| 2025-01-17 | NORRY ELLIOT | Officer | 5,584 | $3,243 | |
| 2025-01-15 | BERTRAND WILLIAM C JR | Chief Operating Officer | 19,542 | $11,360 | |
| 2025-01-15 | RAWCLIFFE ADRIAN | Chief Executive Officer | 59,569 | $34,639 | |
| 2025-01-15 | LUNGER JOHN | Officer | 19,542 | $11,360 |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-18